Point sur les cancers du poumon en 2010

B. Besse; S. Vignot; J. C. Soria

doi:10.1684/bdc.2010.1026

Point sur les cancers du poumon en 2010

Translated title of the contribution: Lung cancer: An update in 2010

B. Besse, S. Vignot, J. C. Soria

Research output: Contribution to journal › Article › peer-review

2 Citations (Scopus)

Abstract

The year 2009 has lead to new data clearly impacting therapeutic management strategies in NSCLC. Personalized medicine is becoming a reality for patients with EGFR mutation as well as for the recruitment of patients in certain clinical trials (EML4-ALK translocation, KRAS mutation...). Maintenance trials are based on questionable statistical designs but this approach may have an interest in certain subset of patients. Little improvements are being achieved in SCLC and locally advanced NSCLC.

Translated title of the contribution	Lung cancer: An update in 2010
Original language	French
Pages (from-to)	161-169
Number of pages	9
Journal	Bulletin du Cancer
Volume	97
Issue number	1
DOIs	https://doi.org/10.1684/bdc.2010.1026
Publication status	Published - 1 Jan 2010

Access to Document

10.1684/bdc.2010.1026

Cite this

@article{7ebe12de26414c279eccbedbaeca26d5,

title = "Point sur les cancers du poumon en 2010",

abstract = "The year 2009 has lead to new data clearly impacting therapeutic management strategies in NSCLC. Personalized medicine is becoming a reality for patients with EGFR mutation as well as for the recruitment of patients in certain clinical trials (EML4-ALK translocation, KRAS mutation...). Maintenance trials are based on questionable statistical designs but this approach may have an interest in certain subset of patients. Little improvements are being achieved in SCLC and locally advanced NSCLC.",

keywords = "Chemotherapy, EGFR, Lung cancer, Maintenance, Targeted therapies",

author = "B. Besse and S. Vignot and Soria, {J. C.}",

year = "2010",

month = jan,

day = "1",

doi = "10.1684/bdc.2010.1026",

language = "Fran{\c c}ais",

volume = "97",

pages = "161--169",

journal = "Bulletin du Cancer",

issn = "0007-4551",

number = "1",

}

TY - JOUR

T1 - Point sur les cancers du poumon en 2010

AU - Besse, B.

AU - Vignot, S.

AU - Soria, J. C.

PY - 2010/1/1

Y1 - 2010/1/1

N2 - The year 2009 has lead to new data clearly impacting therapeutic management strategies in NSCLC. Personalized medicine is becoming a reality for patients with EGFR mutation as well as for the recruitment of patients in certain clinical trials (EML4-ALK translocation, KRAS mutation...). Maintenance trials are based on questionable statistical designs but this approach may have an interest in certain subset of patients. Little improvements are being achieved in SCLC and locally advanced NSCLC.

AB - The year 2009 has lead to new data clearly impacting therapeutic management strategies in NSCLC. Personalized medicine is becoming a reality for patients with EGFR mutation as well as for the recruitment of patients in certain clinical trials (EML4-ALK translocation, KRAS mutation...). Maintenance trials are based on questionable statistical designs but this approach may have an interest in certain subset of patients. Little improvements are being achieved in SCLC and locally advanced NSCLC.

KW - Chemotherapy

KW - EGFR

KW - Lung cancer

KW - Maintenance

KW - Targeted therapies

UR - http://www.scopus.com/inward/record.url?scp=75749098539&partnerID=8YFLogxK

U2 - 10.1684/bdc.2010.1026

DO - 10.1684/bdc.2010.1026

M3 - Article

C2 - 20028651

AN - SCOPUS:75749098539

SN - 0007-4551

VL - 97

SP - 161

EP - 169

JO - Bulletin du Cancer

JF - Bulletin du Cancer

IS - 1

ER -

Point sur les cancers du poumon en 2010

Abstract

Access to Document

Other files and links

Cite this